login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SANGAMO THERAPEUTICS INC (SGMO) Stock News
USA
- NASDAQ:SGMO -
US8006771062
-
Common Stock
0.485
USD
-0.02 (-3%)
Last: 11/12/2025, 1:34:51 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SGMO Latest News, Press Relases and Analysis
All
Press Releases
6 days ago - By: Chartmill
Sangamo Therapeutics Inc (NASDAQ:SGMO) Stock Plummets 22% After Q3 Earnings Miss
6 days ago - By: Chartmill
- Mentions:
CCOI
ASTI
ASPN
ELF
...
Stay updated with the stocks that are on the move in today's pre-market session.
2 days ago - By: Benzinga
- Mentions:
NNVC
REVB
CYCN
CNSP
...
12 Health Care Stocks Moving In Monday's After-Market Session
5 days ago - By: Benzinga
- Mentions:
CCOI
XRAY
KMX
GDEN
This CarMax Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
6 days ago - By: The Motley Fool
- Mentions:
PFE
Sangamo (SGMO) Q3 2025 Earnings Call Transcript
6 days ago - By: Sangamo Therapeutics, Inc.
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
13 days ago - By: Sangamo Therapeutics, Inc.
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call
2 months ago - By: Sangamo Therapeutics, Inc.
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
3 months ago - By: Zacks Investment Research
What Makes Sangamo (SGMO) a New Buy Stock
3 months ago - By: Zacks Investment Research
- Mentions:
CRVO
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
3 months ago - By: Sangamo Therapeutics, Inc.
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results
5 months ago - By: Sangamo Therapeutics, Inc.
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
6 months ago - By: Sangamo Therapeutics, Inc.
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
6 months ago - By: Sangamo Therapeutics, Inc.
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
6 months ago - By: Zacks Investment Research
- Mentions:
ARMP
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
6 months ago - By: Sangamo Therapeutics, Inc.
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
6 months ago - By: Zacks Investment Research
- Mentions:
NVAX
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates
6 months ago - By: Sangamo Therapeutics, Inc.
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call
6 months ago - By: Sangamo Therapeutics, Inc.
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
6 months ago - By: Zacks Investment Research
- Mentions:
RGNX
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
7 months ago - By: Zacks Investment Research
- Mentions:
QGEN
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
7 months ago - By: Sangamo Therapeutics, Inc.
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Please enable JavaScript to continue using this application.